BRCA1 and ovarian cancer: Despite International guidelines recommending testing for patients with high grade serous ovarian cancer (HGSOC) for germline BRCA1 and BRCA2 pathological variants, the uptake of genetic testing in this patient group remains low, with 19.6% of eligible patients with ovarian cancer declining test [10, 11].